Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease

Running, not enrolling · Not applicable

Conditions studied: Sickle Cell Disease

In brief

Sickle cell disease (SCD) is associated with significant morbidity and mortality. Pain and many adverse outcomes occurring in sickle cell disease are inflammatory driven. Recent data has shown that gut dysbiosis is present in individuals with sickle cell disease. Gut dysbiosis has been linked to inflammation in certain diseases. Omega -3-fatty acids (fish oil) has been shown to improve pain outcomes in individuals with sickle cell disease, but its acceptance is variable. The aim of this study is to determine if a plant-based omega-3-fatty acids will be more acceptable and also improve outcomes in individuals with sickle cell disease

Key facts

Study ID

NCT05758766

Run by

University of Alabama at Birmingham

People needed

30

Starts

2023-08-30

Expected to finish

2026-12-30

Last updated by the study team

2026-01-23

Who can join

Age: 5 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of sickle cell anemia HbSS or HbSB0 thal at steady state
• Age 5-18 years old

You may not qualify if…

• Age less than 5 years
• Age > 18 years old
• Chronic transfusion therapy
• Known to be pregnant
• Breastfeeding mothers
• Current use of antibiotics
• Use of pre or probiotic supplements
• PPI therapy
• Known allergy to FS

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.